1. **Japan's Eisai weighs legal action in UK cancer drug row – Reuters**
   Japan's Eisai said on Friday it would consider all options, including possible legal action, to fight delays in Britain's healthcare system that prevent patients from accessing one of its drugs to treat a rare form of cancer. The move highlights frustration among drugmakers at the way the National Health Service (NHS) restricts access to new drugs, especially ones for cancer that can cost tens of thousands of pounds a year.

2. **India should reject efforts weakening access to generic drugs – Business Standard**
   Describing India's pharmaceutical sector a vital life-line for millions of people in developing countries, an international relief organisation on Thursday, called on Prime Minister Narendra Modi not to cave in to corporate pressure and support people's access to generic medicines to combat deadly diseases like AIDS. "Doctors Without Borders (MSF) urges the Indian government to safeguard its role in supplying affordable, generic medicines to millions of people in South Africa and the rest of the continent," said Claire Waterhouse, MSF Access Campaign Advocacy Officer in Southern Africa.

3. **Lupin gets Establishment Inspection Report from USFDA for Goa facility - The Economic Times**
   Pharma firm Lupin has received Establishment Inspection Report (EIR) from the US health regulator for its Goa facility regarding a inspection done by the USFDA in July last year. The company "has received notification that the inspection carried out by the United States Food and Drug Administration (USFDA) in July 2015 at its Goa facility is now closed and the agency has now issued an EIR," Lupin said in a filing to BSE.

4. **Brick-and-mortar pharmacies selling medicines without demanding prescription: Study – The Economic Times**
   Even as chemists in India have threatened another strike over weak regulation of mushrooming online pharmacies, a new study has revealed that a large number of brick-and-mortar pharmacies continue to sell medicines without demanding a prescription. The study comes while a sub-committee of the health ministry is still evaluating online pharmacies here. The committee, set up last October following a strike by chemists for similar reasons, is finalising recommendations to regulate e-pharmacies and may release a draft on July 8.

5. **Now, chemists to take on e-pharmacies in court – The Economic Times**
   The All India Organisation of Chemists and Druggists (AIOCD) will approach ten high courts in India against the central and state drug regulators for lack of action against the "illegal" operation of online pharmacies, which could compromise patient safety. Online pharmacies, on their part, are gearing up for the fight in the hope that it would clarify misconceptions about the process they follow and also "expose" the public safety hazards that offline pharmacies pose.

6. **Drug industry CEOs lead new task force on Brexit's pharma fallout – The Economic Times**
   Drug industry and government officials have set up a task force to address regulatory and other problems facing the pharmaceutical sector following Britain's decision to leave the European Union. Drugmakers, which overwhelmingly favoured remaining in the EU, account for 25 per cent of all UK business research spending and companies have warned that Brexit threatens uncertainty, added complexity and potential drug approval delays.

7. **India continues to lead China in pharma exports – Mint**
   India has maintained its lead over China in terms of pharma exports, according to a statement by the ministry of commerce and industry. The country's pharma exports rose 7.55%, from $11.66 billion in 2014 to $12.54 billion in 2015. China's pharma exports rose 5.3% from $6.59 billion to $6.94 billion in the same period. India maintained its lead over China in all major markets including the US, European Union and Africa.

8. **Zydus inks pact with Medicines Patent Pool for Hepatitis-C drug – Business Standard**
   Drug firm Zydus Cadila has inked a generic manufacturing pact with the Medicines Patent Pool for manufacturing global pharma major Bristol-Myers Squibb's daclatasvir tablets used in the treatment of Hepatitis-C. The company "has signed a non-exclusive, royalty free agreement with the Medicines Patent Pool (MPP) for the generic production of Bristol-Myers Squibb's daclatasvir, a novel direct-acting antiviral that is proven to help cure multiple genotypes of the Hepatitis-C Virus," Zydus Cadila said in a statement.

9. **Claris Lifesciences surges on USFDA nod for Tobramycin injection – Business Standard**
   Claris Lifesciences said that it has received the Abbreviated New Drug Application (ANDA) approval for Tobramycin Injection USP, 80mg/2mL and 1,200mg/30mL multiple dose vials, in the US. "Tobramycin Injection is an anti-infective used to treat certain serious infections that are caused by bacteria such as meningitis and other infections of the blood, abdomen (stomach area), lungs, skin, bones, joints, and urinary tract," Claris Lifesciences said in a press release

10. **Drug watchdog again finds Combiflam substandard – Business Standard**
    The Drugs Controller General of India (DCGI) has again found Sanofi's popular painkiller drug, Combiflam, of 'sub-standard' quality, in its latest test last month. It had found the same defect in the medicine in February and April, too. "We are working with the regulatory authorities to initiate recall of the batch concerned. Since consumption from this batch is not likely to cause any adverse health consequences, typically, it would qualify as a Class-3 recall," said a Sanofi India spokesperson.

11. **Biosimilars: A shot in the arm for Biocon's future prescription – Business Standard**
    In an authored article, Bureau chief of Business Standard Bengaluru, Raghu Krishnan talks about biosimilars and its huge R&D spending, despite investor apathy, has started showing results. " Biocon got regulatory approval for its Insulin Glargine in Japan, becoming the first

Indian company to get the nod to sell biosimilar drugs in a developed country. Since then, Biocon's share has risen 54.3 per cent, with investors giving their thumbs up to the move," he added.

12. **Painkiller panel drops experts linked to pharmaceutical industry – The Financial Express**
A group advising the Food and Drug Administration on medical issues abruptly dropped four experts from a panel on prescription painkillers after concerns emerged about apparent ties to the pharmaceutical industry. The panel gathered in Washington on Wednesday for its first meeting, tasked with developing recommendations for the FDA on combating the problem of painkiller abuse and misuse. But four doctors listed on the panel's initial roster were dropped before the meeting.

13. **'Awareness about intellectual property rights is rising in India' – The Times of India**
The Confederation of Indian Industry (CII) in association with the department of industrial policy and promotion (DIPP) on Wednesday organized a workshop on intellectual property right (IPR) awareness and national intellectual property right policy at SIDCUL in Haridwar. Rajesh Kohli, additional general manager, BHEL, said, "Much of the IP created remains unprotected both on the account of lack of awareness and the perception that IP protection is either not required, or the process to obtain it is unnecessarily complicated."

14. **Testing for gene mutation can predict prostate cancer risk – The Times of India**
Testing for inherited mutations that are found in much higher rates in men can help in predicting the risk of prostate cancer, finds a study. The findings by researchers in the US revealed that 11.8 per cent of men with metastatic prostate cancer had mutations in at least one gene known to help repair Deoxyribonucleic acid (DNA) -- such as BRCA1 and BRCA2.

15. **SC asks govt to make public Rotavac trials data – Times of India**
The Supreme Court has issued notices to the health ministry, the department of biotechnology and the Christian Medical College, Vellore, on a public interest petition demanding that detailed data of clinical trials on anti-diarrhoea vaccine Rotavac be made public. The trials, conducted on 6,799 infants between 2011 and 2013, to gauge the safety and efficacy of the vaccine, were spread over three centres - Pune, Delhi and Vellore. While combined data for the three centres has been made public, centre-wise data has been kept secret. In March this year immunisation with Rotavac was launched in four states with plans to include it in the Centre's universal immunisation policy. Informed consent requires the disclosure of safety data, and it would be unethical to proceed with immunisation without informing the public of any risks observed with previous use of the vaccine, stated the petition.

16. **Telangana DCA writes to Maharashtra to inspect pharma co. – The Hindu**
The Telangana's Drug Control Administration has written to its Maharashtra counterpart to inspect Haseeb Pharmaceuticals, the manufacturer that supplied RL Solution which is now being blamed for bacterial infection in 13 patients of Sarojini Devi Eye Hospital. As part of the investigation to determine the reasons behind the infection, the DCA had collected 48 bottles from three batches of Ringer's Lactate (RL saline) solution from the hospital for testing at the State's laboratories. The RL Solution was used for ocular irrigation or for washing the eye during surgery.

17. **AKCDA wants Centre to review policy of allowing higher FDI in pharma sector – Pharmabiz.com**
A resolution passed in the annual general body meeting of the All Kerala Chemists and Druggists Association (AKCDA) urged the Union government to review its policy allowing foreign direct investment upto 74 per cent in existing Indian companies and 100 per cent in Greenfield projects. The resolution says that the Centre's decision to allow 74 per cent FDI in Brownfield pharmaceutical projects in automatic route will lead to a collapse of both the Indian manufacturing industry and the trade industry in the country. So, immediately government should withdraw its decision to allow FDI in the Indian pharma sector.